Last reviewed · How we verify
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide (RENEW 2)
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.
Details
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 330 |
| Start date | Wed Nov 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Jun 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Overweight
- Obesity
- Type 2 Diabetes
Interventions
- Cagrilintide
- Placebo (matched to Cagrilintide)
Countries
Slovakia, United Kingdom, Hungary, South Korea, Argentina, Canada, Romania, Switzerland, Croatia, United States, Czechia